Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Introduction: The prognosis of patients with refractory or relapsed AML (R/R‐AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. Patients and Methods: Our retrospective, single‐center study of 53 R/R‐AML patients with a median follow‐up time of 11.0 months compared standard salvage chemotherapy (FLAG‐Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG‐Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy. Results: Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log‐rank‐test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group. Conclusions: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy. [ABSTRACT FROM AUTHOR]